Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis

Jagadeswara R Earla1 Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA

https://orcid.org/0000-0002-6688-5273 View further author information

George J Hutton2 Department of Neurology, Baylor College of Medicine, Houston, TX, USAView further author information

J Douglas Thornton1 Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA

https://orcid.org/0000-0001-6017-7500 View further author information

Hua Chen1 Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USAView further author information

Michael L Johnson1 Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USAView further author information

Rajender R Aparasu1 Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USACorrespondence[email protected]

https://orcid.org/0000-0003-2310-901X View further author information

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Aleksandra Kołtuniuk, Aleksandra Pytel, Dorota Krówczyńska & Justyna Chojdak-Łukasiewicz. (2022) The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis—Cross-Sectional Study. International Journal of Environmental Research and Public Health 19:21, pages 14549.
Crossref

Julia O'Mahony, Amber Salter, Beyza Ciftci-Kavaklioglu, Robert J. Fox, Gary R. Cutter & Ruth Ann Marrie. (2022) Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis. Neurology 99:14, pages e1538-e1548.
Crossref

Jacqueline A Nicholas, Natalie C Edwards, Roger A Edwards, Anna Dellarole, Luigi Manca, Danielle E Harlow & Amy L Phillips. (2022) Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying therapy. Multiple Sclerosis Journal - Experimental, Translational and Clinical 8:2, pages 205521732211011.
Crossref

Jieni Li, Soumya G. Chikermane, Jagadeswara R. Earla, George J. Hutton & Rajender R. Aparasu. (2022) FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Multiple Sclerosis and Related Disorders 60, pages 103703.
Crossref

Ashna Talwar, Jagadeswara R. Earla, George J. Hutton & Rajender R. Aparasu. (2022) Prescribing of disease modifying agents in older adults with multiple sclerosis. Multiple Sclerosis and Related Disorders 57, pages 103308.
Crossref

Jin-Ping Zhao, Christelle Berthod, Odile Sheehy, Behrouz Kassaï, Jessica Gorgui & Anick Bérard. (2021) Prevalence and duration of prescribed opioid use during pregnancy: a cohort study from the Quebec Pregnancy Cohort. BMC Pregnancy and Childbirth 21:1.
Crossref

Adam BurkhardJoshua ToliverKaren Rascati. (2021) Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. Journal of Managed Care & Specialty Pharmacy 27:7, pages 915-923.
Crossref

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date